Biocompatibility and pharmacokinetic analysis of an intracameral polycaprolactone drug delivery implant for glaucoma

Kim J., Kudisch M., Mudumba S., Asada H., Aya-Shibuya E., Bhisitkul R.B., Desai T.A.

2016
Investigative Ophthalmology and Visual Science

View publication

Therapeutic Area

Glaucoma
Technology

Drug Delivery

Affiliations

San Francisco, CA, United States; Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, United States; Santen, Inc., Emeryville, CA, United States; Santen Pharmaceutical Co., Ltd., Nara RD Center, Nara, Japan; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, United States

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.

Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.

The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.

View all Glaucoma publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022